Evaluation of antitumor properties of novel saframycin analogs in vitro and in vivo

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 18, 2006, Pages 4884-4888

  Spencer, Jeffrey R ^a   Sendzik, Martin ^a   Oeh, Jason ^a   Sabbatini, Peter ^a   Dalrymple, Stacie A ^a   Magill, Catherine ^a   Kim, Hyunjin M ^a   Zhang, Penglie ^a   Squires, Neil ^a   Moss, Katherine G ^a   Sukbuntherng, Juthamas ^a   Graupe, Doris ^a   Eksterowicz, John ^a   Young, Peter R ^a   Myers, Andrew G ^b   Green, Michael J ^a  

^a CELERA   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

DNA binding; Fluorescence; GI50; In vivo model; Saframycin analog

Indexed keywords

ANTINEOPLASTIC AGENT; QUINALDIC ACID; QUINOLINE DERIVATIVE; SAFRAMYCIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; SOLID TUMOR; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; ISOQUINOLINES; MICE; MICE, INBRED BALB C; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33746825457     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.06.085     Document Type: Article

References (21)

1. Arai T., Takahashi K., and Kubo A. J. Antibiot. (Tokyo) 30 (1977) 1015
2. Arai T., Takahashi K., Ishiguro K., and Yazawa K. J. Antibiot. (Tokyo) 33 (1980) 951
3. For a review, see:. Scott J.D., and Williams R.M. Chem. Rev. 102 (2002) 1669
4. Lown J.W., Joshua A.V., and Lee J.S. Biochemistry 21 (1982) 419
5. Moore II B.M., Seaman F.C., and Hurley L.H. J. Am. Chem. Soc. 119 (1997) 5475
6. Arai T., Takahashi K., Ishiguro K., and Mikami Y. Gann 71 (1980) 790
7. Kaneda S., Hour-Yong C., Yazawa K., Takahashi K., Mikami Y., and Arai T. Jpn. J. Cancer Res. 77 (1986) 1043
8. For a review, see:. Beumer J.H., Schellens J.H., and Beijnen J.H. Pharmacol. Res. 51 (2005) 391
9. Myers A.G., and Kung D.W. J. Am. Chem. Soc. 121 (1999) 10828
10. Myers A.G., and Plowright A.T. J. Am. Chem. Soc. 123 (2001) 5114
11. Martinez E.J., Owa T., Schreiber S.L., and Corey E.J. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 3496
12. For comparison, the reported growth inhibition of A549 lung tumor cells and A375 melanoma cells by ET-743 is 1.0 and 0.15 nM, respectively, as reported in part (a).
13. Ishiguro K., Takahashi K., Yazawa K., Sakiyama S., and Arai T. J. Biol. Chem. 256 (1981) 2162
14. Krynetski E.Y., Krynetskaia N.F., Gallo A.E., Murti K.G., and Evans W.E. Mol. Pharmacol. 59 (2001) 367
15. Takebayashi Y., Pourquier P., Yoshida A., Kohlhagen G., and Pommier Y. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 7196
16. Xing C., LaPorte J.R., Barbay J.K., and Myers A.G. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 5862
17. Rao K.E., and Lown J.W. Biochemistry 31 (1992) 12076
18. Seaman F.C., and Hurley L.H. J. Am. Chem. Soc. 120 (1998) 13028
19. García-Nieto R., Manzanares I., Cuevas C., and Gago F. J. Am. Chem. Soc. 122 (2000) 7172
20. Figure S1 is contained in supplementary material which may be accessed online alongside the article.
21. iv.